Acute disseminated encephalomyelitis (ADEM) mostly occurs in children and can be triggered by infections and vaccinations. Recently, 40% of patients with ADEM were found to be seropositive for myelin oligodendrocyte glycoprotein antibodies (MOG-abs).^[@R1]^ Furthermore, a subgroup of adult patients negative for aquaporin-4 antibody fulfilling diagnostic clinical and radiologic criteria for neuromyelitis optica spectrum disorder (NMOSD) harbor high-titer serum MOG-abs.^[@R2]^ We present clinical, serologic, and histopathologic features of 2 adult patients with a clinical diagnosis of ADEM according to the diagnostic criteria^[@R3]^ associated with intrathecal MOG-abs synthesis. MOG-abs were determined by live-cell immunofluorescence on HEK293T cells expressing full-length human MOG-enhanced green fluorescent protein at a starting dilution of 1:20 in serum and 1:2 in CSF using an epifluorescence microscope and end-point titration as previously described.^[@R2]^

Case reports. {#s1-1}
=============

Case report 1. {#s1-1-1}
--------------

A 49-year-old man developed subacute encephalopathy with bradyphrenia, dysphoria, and anhedonia together with progressive central paresis of the right leg, a sensory level below TH10, myalgia, and deteriorated to tetraparesis despite treatment with aciclovir, ceftriaxone, and methylprednisolone. No preceding infections, vaccinations, or prior neurologic symptoms were reported. MRI showed extensive spinal cord and cerebral lesions ([figure 1, A and B,](#F1){ref-type="fig"} and figure e-1 at [Neurology.org/nn](10.1212/NXI.0000000000000335)). CSF analysis demonstrated pleocytosis (133 white blood cells \[WBCs\]/μL) and elevated protein (1,572 mg/L) without CSF-restricted oligoclonal IgG. No infectious agents were detected. Brain biopsy performed 4 weeks after the onset of symptoms showed active, confluent demyelination with IgG and complement deposition, perivascular and parenchymal B- and T-cell accumulation, parenchymal macrophage infiltration, and oligodendrocyte apoptosis associated with selective loss of minor myelin proteins consistent with overlapping features of MS patterns II and III ([figure 1, C--G](#F1){ref-type="fig"}). Plasma exchange and intravenous cyclophosphamide led to improvement. No new clinical or radiologic activity was observed on follow-up (17 months).

![Neuropathology of MOG-antibody--associated demyelination\
Case 1 (A--G): MRI showed large bilateral hazy, partly Gd-enhancing lesions in the deep white matter and periventricular zone (A, left axial-fluid-attenuated inversion recovery (FLAIR), right Gd-enhanced axial T1) that regressed partially during follow-up (B, axial-FLAIR). Histopathology showed a demyelinating lesion (C, Luxol fast blue) and inflammatory infiltrates mainly composed of CD8-positive T cells (D, CD8; arrow). The lesion showed deposits of activated complement complex C9neo on degenerating fibers and in macrophages (E). In early active demyelinating lesion zones, MOG was still present (F; MOG), while myelin-associated glycoprotein (MAG) was lost (G; MAG). Case 2 (H--N): MRI showed large bilateral hazy lesions in the deep white matter and periventricular zone as well as gadolinium rim-enhancing, well-demarcated lesions in the deep white matter (H, left axial-FLAIR, right Gd-enhanced axial T1) that regressed on follow-up (I, axial-FLAIR). Biopsy of a ring-enhancing lesion revealed a well-demarcated demyelinating lesion (J, Luxol fast blue), T-cell dominated inflammation (K, CD8), and mild perivascular complement deposition (L, C9neo; arrows) reminiscent of MS pattern II. Numerous remyelinating oligodendrocytes were encountered (M, tubulin polymerization promoting protein/p25) that were partly MOG positive (N; MOG; arrows). Magnification: C--G; L--N: ×400; J, K: ×100 (MRIs \[A, B\] from the Institute of Neuroradiology, Magdeburg, Germany). Further panels are provided in figure e-1. MOG = myelin oligodendrocyte glycoprotein.](NEURIMMINFL2016011577FF1){#F1}

Retrospective analysis of the initial CSF and serum confirmed MOG-abs (IgG1, IgG3, and IgM) in the CSF (IgG 1:64, follow-up 17 months later 1:2) and serum (IgG 1:160, follow-up 17 months later 1:40). Initial intrathecal MOG-abs-IgG index was 22.3 (\<4, total IgG-CSF 0.143 g/L, serum 8.0 g/L).

Case report 2. {#s1-1-2}
--------------

A 34-year-old man presented with aphasia and somnolence followed by hypesthesia and paresis of lower extremities, bladder dysfunction, and ataxia. MRI showed multiple cerebral and spinal lesions ([figures 1, H and I](#F1){ref-type="fig"} and e-1). CSF studies revealed pleocytosis (151 WBCs/μL), elevated protein (1,260 mg/L), and CSF-restricted oligoclonal bands. Biopsy 6 weeks after symptom onset showed a confluent, well-demarcated demyelinating lesion with a rim of parenchymal macrophages, T-cell--dominated inflammation, and mild complement deposition, reminiscent of MS pattern II ([figure 1, J--N](#F1){ref-type="fig"}). The patient responded well to treatment with methylprednisolone, IV immunoglobulin (IVIG), and plasma exchange. Three-month follow-up showed regression of MRI lesions. CSF-restricted oligoclonal bands were still present. Last follow-up 9 months after the onset did not reveal any new clinical or radiologic activity.

Retrospective serum and CSF analyses confirmed IgG and IgM MOG-abs (initial serum 1:80, CSF 1:16; 3-month follow-up serum \<1:40, CSF \<1:2). Initial intrathecal MOG-abs-IgG index was 32.4 (\<4, total IgG-CSF 0.073 g/L, serum 1.2 g/L).

Discussion. {#s1-2}
===========

We report 2 adult patients with a subacute, multifocal clinical presentation with encephalopathy and MRI features fulfilling clinical diagnostic criteria of ADEM,^[@R3]^ who both had (1) an MS-like histopathology on brain biopsy and (2) intrathecal MOG-abs synthesis.

Pathologically, ADEM is distinct from MS with minor perivascular demyelination in ADEM vs confluent plaque--like demyelination in MS while both conditions share perivascular inflammation. Neuropathologic reports of MOG-abs--associated demyelination are scarce and show MS typical confluent demyelination with astrocyte preservation in a patient with a clinical syndrome of NMOSD,^[@R4]^ MS pattern II--like pathology in a patient with a clinically isolated syndrome,^[@R5]^ a patient fulfilling criteria for relapsing MS,^[@R6]^ and an overlap of pathologic MS and NMOSD features in a patient clinically classified as ADEM, who also had anti--aquaporin-4 antibodies.^[@R7]^

Our cases imply that, although clinically and radiologically presenting as ADEM-like syndrome, MOG-abs--associated demyelinating disorders could pathologically resemble MS.

MOG-abs are increasingly recognized in adult patients with inflammatory CNS demyelination with a yet-to-be-defined spectrum encompassing NMOSD, ADEM, and uni- or bilateral isolated optic neuritis (ON).^[@R1]^ They are considered as highly sensitive and specific when tested with appropriate methods using live (unfixed) cell-based assays. MOG-abs are more consistently detected in the serum than in the CSF, and intrathecal MOG-abs synthesis is unusual.^[@R2]^ While CSF MOG-abs in children with ADEM are unusual, future systematic examination of adults with multifocal demyelinating CNS syndromes with MOG-abs will hopefully elucidate, whether our observation of intrathecal MOG-abs synthesis is a coincidental or causal association. Our observations (1) indicate that MOG-abs--associated inflammatory demyelination independent of clinical presentation histopathologically resembles MS and (2) should encourage clinicians to test for MOG-abs in inflammatory CNS diseases suggestive of ADEM, ON, or NMOSD in the serum and CSF using appropriate test methods.
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###### Data Supplement

Supplemental data at [Neurology.org/nn](10.1212/NXI.0000000000000335)
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